GvHD – VJRegenMed

CYP-001 in adults with steroid-resistant GvHD

Simon Ng — Tue, 03 May 2022 16:17:07 +0000

Mesenchymal stem cells (MSCs) derived from induced pluripotent stem cells (iPSCs) have shown promising efficacy as a cell therapy. Ross Macdonald, PhD, Cynata Therapeutics, Melbourne, Australia, discusses results from a Phase I trial (NCT02923375) assessing CYP-001, a MSC-based cell therapy in patients with steroid resistant graft-versus-host disease (GvHD). For patients who progress from corticosteroids, treatment options remain poor and mortality remains high. CYP-001 resulted in a complete response in over half of the cohort and after a two year follow-up, a survival rate of over 50% was reported. This interview was conducted during Meeting on the Mediterranean 2022.

Overcoming barriers in treating liquid tumors with T-cell therapies

Simon Ng — Thu, 07 Apr 2022 13:19:56 +0000

Michela Consonni, PhD, San Raffaele Scientific Institute, Millan, Italy, comments on what needs to be addressed to optimize chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) therapies for leukemias and lymphomas. Further research is required to discover novel antigen targets solely expressed on tumors to avoid off-target side effects and to prevent antigen escape. Additional TCRs are also necessary for TCR-T cells to be compatible with a wider range of human leukocyte antigens (HLAs). Dr Consonni additionally highlights the risk of graft versus host disease (GvHD) in patients receiving hematopoietic stem cell transplantation (HSCT). This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

The anti-leukemic potential of CD1c-restricted T cells

Simon Ng — Wed, 06 Apr 2022 13:26:05 +0000

Michela Consonni, PhD, San Raffaele Scientific Institute, Millan, Italy, gives an overview of newly identified methyl-lysophosphatidic acids (mLPAs) that are highly expressed in leukemia cells and are presented by CD1c, a monomorphic major histocompatibility complex (MHC) class I-like molecule. CD1c-restricted T lymphocytes have found to target CD1c+ leukemia cells and Dr Consonni highlights the advantages of these lipid-specific T cells as an alternative to existing T-cell therapies, including the lower risk of graft versus host disease (GvHD) as a result of CD1c being solely expressed in hematopoietic cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

The benefits of umbilical cord-derived MSCs as a cell source

admin_vjr_user — Wed, 13 Oct 2021 17:11:11 +0000

Mathias Svahn, PhD, MScEng, NextCell Pharma AB, Huddinge, Sweden, gives an overview of the use and benefits of umbilical cord (UC)-derived mesenchymal stem cell (MSC) as a cell source for cell-based therapeutics. Compared to bone marrow-derived MSCs, which have been under investigation in a range of autoimmune conditions and graft-versus-host disease for a number of years, UC-MSCs have more recently started being utilized and investigated. UC-MSCs constitute a young, potent and fast-growing source of cells that can be obtained from discarded tissue, thus reducing ethical implications. This interview took place at the Advanced Therapies Congress & Expo 2021.

Functional dosing of MSC-derived extracellular vesicles for the prevention of GvHD

admin_vjr_user — Wed, 19 Aug 2020 16:20:19 +0000

Mauro Krampera, MD, PhD, of the University of Verona, Verona, Italy, outlines the use of mesenchymal stromal cell (MSC)-derived extracellular vesicles for the prevention of acute graft-versus-host disease (GvHD). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).